Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 315

1.

Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma.

Rini BI, McDermott DF, Hammers H, Bro W, Bukowski RM, Faba B, Faba J, Figlin RA, Hutson T, Jonasch E, Joseph RW, Leibovich BC, Olencki T, Pantuck AJ, Quinn DI, Seery V, Voss MH, Wood CG, Wood LS, Atkins MB.

J Immunother Cancer. 2016 Nov 15;4:81. eCollection 2016.

2.

Creating diversified response profiles from a single quenchometric sensor element by using phase-resolved luminescence.

Tehan EC, Bukowski RM, Chodavarapu VP, Titus AH, Cartwright AN, Bright FV.

Sensors (Basel). 2015 Jan 5;15(1):760-8. doi: 10.3390/s150100760.

3.

Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma.

Hutson TE, Bukowski RM, Rini BI, Gore ME, Larkin JM, Figlin RA, Barrios CH, Escudier B, Lin X, Fly K, Martell B, Matczak E, Motzer RJ.

Br J Cancer. 2014 Mar 4;110(5):1125-32. doi: 10.1038/bjc.2013.832. Epub 2014 Jan 16.

4.

The Cost of Hope: a candid roundtable discussion.

Bennett A, Bukowski RM, Flaherty K, Muir JC, Turner CD, Donaldson S.

J Natl Compr Canc Netw. 2013 May;11(5 Suppl):633-5.

PMID:
23704231
5.

Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma.

Choueiri TK, Vaishampayan U, Rosenberg JE, Logan TF, Harzstark AL, Bukowski RM, Rini BI, Srinivas S, Stein MN, Adams LM, Ottesen LH, Laubscher KH, Sherman L, McDermott DF, Haas NB, Flaherty KT, Ross R, Eisenberg P, Meltzer PS, Merino MJ, Bottaro DP, Linehan WM, Srinivasan R.

J Clin Oncol. 2013 Jan 10;31(2):181-6. doi: 10.1200/JCO.2012.43.3383. Epub 2012 Dec 3.

6.

Temsirolimus: a safety and efficacy review.

Bukowski RM.

Expert Opin Drug Saf. 2012 Sep;11(5):861-79. doi: 10.1517/14740338.2012.713344. Epub 2012 Aug 6. Review.

PMID:
22861825
7.

Differing von hippel lindau genotype in paired primary and metastatic tumors in patients with clear cell renal cell carcinoma.

Vaziri SA, Tavares EJ, Golshayan AR, Rini BI, Aydin H, Zhou M, Sercia L, Wood L, Ganapathi MK, Bukowski RM, Ganapathi R.

Front Oncol. 2012 May 28;2:51. doi: 10.3389/fonc.2012.00051. eCollection 2012.

8.

Third generation tyrosine kinase inhibitors and their development in advanced renal cell carcinoma.

Bukowski RM.

Front Oncol. 2012 Feb 15;2:13. doi: 10.3389/fonc.2012.00013. eCollection 2012.

9.
10.

Critical appraisal of pazopanib as treatment for patients with advanced metastatic renal cell carcinoma.

Bukowski RM.

Cancer Manag Res. 2011;3:273-85. doi: 10.2147/CMR.S15557. Epub 2011 Aug 10.

11.

Biomarkers in renal cell carcinoma: what next?

Bukowski RM.

Curr Oncol Rep. 2011 Apr;13(2):87-9. doi: 10.1007/s11912-011-0155-2. No abstract available.

PMID:
21271363
12.

Phase I/II trial of subcutaneous interleukin-2, granulocyte-macrophage colony-stimulating factor and interferon-α in patients with metastatic renal cell carcinoma.

Garcia JA, Mekhail T, Elson P, Wood L, Bukowski RM, Dreicer R, Rini BI.

BJU Int. 2012 Jan;109(1):63-9. doi: 10.1111/j.1464-410X.2010.10011.x. Epub 2011 Jan 18.

13.

Genitourinary oncology: current status and future challenges.

Bukowski RM.

Front Oncol. 2011 Oct 10;1:32. doi: 10.3389/fonc.2011.00032. eCollection 2011. No abstract available.

14.
15.

Burden of metastatic bone disease from genitourinary malignancies.

Mulders PF, Abrahamsson PA, Bukowski RM.

Expert Rev Anticancer Ther. 2010 Nov;10(11):1721-33. doi: 10.1586/era.10.136. Review.

PMID:
21080800
16.

Clinical and immunomodulatory effects of bevacizumab and low-dose interleukin-2 in patients with metastatic renal cell carcinoma: results from a phase II trial.

Garcia JA, Mekhail T, Elson P, Triozzi P, Nemec C, Dreicer R, Bukowski RM, Rini BI.

BJU Int. 2011 Feb;107(4):562-70. doi: 10.1111/j.1464-410X.2010.09573.x. Epub 2010 Sep 14.

17.

Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab.

Garcia JA, Hutson TE, Elson P, Cowey CL, Gilligan T, Nemec C, Dreicer R, Bukowski RM, Rini BI.

Cancer. 2010 Dec 1;116(23):5383-90. doi: 10.1002/cncr.25327. Epub 2010 Aug 30.

18.

Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access program.

Bukowski RM, Stadler WM, McDermott DF, Dutcher JP, Knox JJ, Miller WH Jr, Hainsworth JD, Henderson CA, Hajdenberg J, Kindwall-Keller TL, Ernstoff MS, Drabkin HA, Curti BD, Chu L, Ryan CW, Hotte SJ, Xia C, Cupit L, Figlin RA.

Oncology. 2010;78(5-6):340-7. doi: 10.1159/000320223. Epub 2010 Aug 20.

PMID:
20733337
19.

A phase II study of tandutinib (MLN518), a selective inhibitor of type III tyrosine receptor kinases, in patients with metastatic renal cell carcinoma.

Shepard DR, Cooney MM, Elson P, Bukowski RM, Dreicer R, Rini BI, Garcia JA.

Invest New Drugs. 2012 Feb;30(1):364-7. doi: 10.1007/s10637-010-9516-1. Epub 2010 Aug 14.

PMID:
20711630
20.

Sequential use of targeted agents in the treatment of renal cell carcinoma.

Hutson TE, Bukowski RM, Cowey CL, Figlin R, Escudier B, Sternberg CN.

Crit Rev Oncol Hematol. 2011 Jan;77(1):48-62. doi: 10.1016/j.critrevonc.2010.07.018. Epub 2010 Aug 11. Review.

PMID:
20705477
21.

A phase I dose escalation study of TTI-237 in patients with advanced malignant solid tumors.

Wang-Gillam A, Arnold SM, Bukowski RM, Rothenberg ML, Cooper W, Wang KK, Gauthier E, Lockhart AC.

Invest New Drugs. 2012 Feb;30(1):266-72. doi: 10.1007/s10637-010-9506-3. Epub 2010 Aug 10.

PMID:
20697774
22.

Biomarkers predicting outcome in patients with advanced renal cell carcinoma: Results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial.

Peña C, Lathia C, Shan M, Escudier B, Bukowski RM.

Clin Cancer Res. 2010 Oct 1;16(19):4853-63. doi: 10.1158/1078-0432.CCR-09-3343. Epub 2010 Jul 22.

23.

Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.

Chan HY, Grossman AB, Bukowski RM.

Adv Ther. 2010 Aug;27(8):495-511. doi: 10.1007/s12325-010-0045-2. Epub 2010 Jul 8. Review.

PMID:
20623346
24.

Systemic therapy for metastatic renal cell carcinoma in treatment naïve patients: a risk-based approach.

Bukowski RM.

Expert Opin Pharmacother. 2010 Oct;11(14):2351-62. doi: 10.1517/14656566.2010.499126. Review.

PMID:
20586712
25.

Pazopanib: a multikinase inhibitor with activity in advanced renal cell carcinoma.

Bukowski RM.

Expert Rev Anticancer Ther. 2010 May;10(5):635-45. doi: 10.1586/era.10.38. Review.

PMID:
20469994
26.

RANK ligand: effects of inhibition.

George S, Brenner A, Sarantopoulos J, Bukowski RM.

Curr Oncol Rep. 2010 Mar;12(2):80-6. doi: 10.1007/s11912-010-0088-1. Review.

PMID:
20425591
27.

Molecular genetic events associated with renal cell carninoma and its implication to treatment by molecular target therapy.

Kishida T, Yao M, Uemura H, Ohlmann C, Tomita Y, Bukowski RM, Naito S.

Int J Urol. 2010 Mar;17(3):198-205. doi: 10.1111/j.1442-2042.2010.02455.x. No abstract available.

28.

Stable disease in renal cell carcinoma after using signal transduction inhibitors.

George S, Shah SN, Bukowski RM.

Rev Recent Clin Trials. 2010 May;5(2):117-22. Review.

PMID:
20199387
29.

Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America.

Stadler WM, Figlin RA, McDermott DF, Dutcher JP, Knox JJ, Miller WH Jr, Hainsworth JD, Henderson CA, George JR, Hajdenberg J, Kindwall-Keller TL, Ernstoff MS, Drabkin HA, Curti BD, Chu L, Ryan CW, Hotte SJ, Xia C, Cupit L, Bukowski RM; ARCCS Study Investigators.

Cancer. 2010 Mar 1;116(5):1272-80. doi: 10.1002/cncr.24864.

30.

Pazopanib.

Bukowski RM, Yasothan U, Kirkpatrick P.

Nat Rev Drug Discov. 2010 Jan;9(1):17-8. doi: 10.1038/nrd3073.

PMID:
20043026
31.
32.

Optimizing utilization of targeted therapies in genitourinary cancers.

Bukowski RM.

Clin Genitourin Cancer. 2008 Dec;6 Suppl 1:S6. No abstract available.

PMID:
19891123
33.

Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.

Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S, Venner P, Knox JJ, Chi KN, Kollmannsberger C, McDermott DF, Oh WK, Atkins MB, Bukowski RM, Rini BI, Choueiri TK.

J Clin Oncol. 2009 Dec 1;27(34):5794-9. doi: 10.1200/JCO.2008.21.4809. Epub 2009 Oct 13.

PMID:
19826129
34.

Safety and efficacy of PF-3512676 for the treatment of stage IV renal cell carcinoma: an open-label, multicenter phase I/II study.

Thompson JA, Kuzel T, Drucker BJ, Urba WJ, Bukowski RM.

Clin Genitourin Cancer. 2009 Oct;7(3):E58-65. doi: 10.3816/CGC.2009.n.025.

PMID:
19815483
35.

Role of everolimus in the treatment of renal cell carcinoma.

George S, Bukowski RM.

Ther Clin Risk Manag. 2009 Oct;5(5):699-706. Epub 2009 Sep 15.

36.

A phase I study of sunitinib plus bevacizumab in advanced solid tumors.

Rini BI, Garcia JA, Cooney MM, Elson P, Tyler A, Beatty K, Bokar J, Mekhail T, Bukowski RM, Budd GT, Triozzi P, Borden E, Ivy P, Chen HX, Dolwati A, Dreicer R.

Clin Cancer Res. 2009 Oct 1;15(19):6277-83. doi: 10.1158/1078-0432.CCR-09-0717. Epub 2009 Sep 22.

37.

Inhibition of proteasome activity by bortezomib in renal cancer cells is p53 dependent and VHL independent.

Vaziri SA, Grabowski DR, Hill J, Rybicki LR, Burk R, Bukowski RM, Ganapathi MK, Ganapathi R.

Anticancer Res. 2009 Aug;29(8):2961-9.

38.

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma.

Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garcia-del-Muro X, Sosman JA, Solska E, Wilding G, Thompson JA, Kim ST, Chen I, Huang X, Figlin RA.

J Clin Oncol. 2009 Aug 1;27(22):3584-90. doi: 10.1200/JCO.2008.20.1293. Epub 2009 Jun 1.

39.

Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.

Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Staehler M, Negrier S, Chevreau C, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Anderson S, Hofilena G, Shan M, Pena C, Lathia C, Bukowski RM.

J Clin Oncol. 2009 Jul 10;27(20):3312-8. doi: 10.1200/JCO.2008.19.5511. Epub 2009 May 18.

PMID:
19451442
40.

Prognostic factors for survival in metastatic renal cell carcinoma: update 2008.

Bukowski RM.

Cancer. 2009 May 15;115(10 Suppl):2273-81. doi: 10.1002/cncr.24226. Review.

41.

Innovations and challenges in renal cancer: summary statement from the Third Cambridge Conference.

Atkins MB, Bukowski RM, Escudier BJ, Figlin RA, Hudes GH, Kaelin WG Jr, Linehan WM, McDermott DF, Mier JW, Pedrosa I, Rini BI, Signoretti S, Sosman JA, Teh BT, Wood CG, Zurita AJ, King L.

Cancer. 2009 May 15;115(10 Suppl):2247-51. doi: 10.1002/cncr.24229.

42.

Targeted Therapies: Bevacizumab and interferon-alpha in metastatic renal-cell carcinoma.

Bukowski RM.

Nat Rev Clin Oncol. 2009 May;6(5):253-4. doi: 10.1038/nrclinonc.2009.45.

PMID:
19390549
43.

A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors.

Wong KK, Fracasso PM, Bukowski RM, Lynch TJ, Munster PN, Shapiro GI, Jänne PA, Eder JP, Naughton MJ, Ellis MJ, Jones SF, Mekhail T, Zacharchuk C, Vermette J, Abbas R, Quinn S, Powell C, Burris HA.

Clin Cancer Res. 2009 Apr 1;15(7):2552-8. doi: 10.1158/1078-0432.CCR-08-1978. Epub 2009 Mar 24.

44.

Myeloid-derived suppressor cells: a novel therapeutic target.

Ko JS, Bukowski RM, Fincke JH.

Curr Oncol Rep. 2009 Mar;11(2):87-93. Review.

PMID:
19216839
45.

Axitinib treatment in patients with cytokine-refractory metastatic renal cell cancer.

Bukowski RM.

Curr Oncol Rep. 2009 Mar;11(2):81-3. No abstract available.

PMID:
19216838
46.

Tyrosine kinase inhibitors in advanced renal cell carcinoma: the evolving treatment paradigm.

Bukowski RM.

Clin Genitourin Cancer. 2009 Jan;7(1):9-10. doi: 10.3816/CGC.2009.n.001. No abstract available.

PMID:
19213661
47.

Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma.

Escudier B, Szczylik C, Hutson TE, Demkow T, Staehler M, Rolland F, Negrier S, Laferriere N, Scheuring UJ, Cella D, Shah S, Bukowski RM.

J Clin Oncol. 2009 Mar 10;27(8):1280-9. doi: 10.1200/JCO.2008.19.3342. Epub 2009 Jan 26. Erratum in: J Clin Oncol. 2009 May 1; 27(13):2305.

PMID:
19171708
48.

A population-based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancer.

Heng DY, Chi KN, Murray N, Jin T, Garcia JA, Bukowski RM, Rini BI, Kollmannsberger C.

Cancer. 2009 Feb 15;115(4):776-83. doi: 10.1002/cncr.24051.

49.

Anti-angiogenic targets in the treatment of advanced renal cell carcinoma.

Heng DY, Bukowski RM.

Curr Cancer Drug Targets. 2008 Dec;8(8):676-82. Review.

PMID:
19075590
50.

Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.

Golshayan AR, George S, Heng DY, Elson P, Wood LS, Mekhail TM, Garcia JA, Aydin H, Zhou M, Bukowski RM, Rini BI.

J Clin Oncol. 2009 Jan 10;27(2):235-41. doi: 10.1200/JCO.2008.18.0000. Epub 2008 Dec 8.

PMID:
19064974

Supplemental Content

Loading ...
Support Center